Durect Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
116
- Stock Symbol
-
DRRX
- Investments
-
2
- Share Price
-
$0.63
- (As of Friday Closing)
Durect General Information
Description
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
Contact Information
Website
www.durect.comCorporate Office
- 10260 Bubb Road
- Cupertino, CA 95014-4166
- United States
Corporate Office
- 10260 Bubb Road
- Cupertino, CA 95014-4166
- United States
Durect Stock Performance
As of 16-May-2025, Durect’s stock price is $0.63. Its current market cap is $19.6M with 31M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.63 | $0.62 | $0.52 - $1.88 | $19.6M | 31M | 81.6K | -$0.14 |
Durect Financials Summary
As of 31-Mar-2025, Durect has a trailing 12-month revenue of $4.42M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 15,299 | 26,645 | 1,768 | 50,492 |
| Revenue | 4,419 | 2,031 | 2,590 | 19,283 |
| EBITDA | 29,765 | 118,241 | 114,918 | |
| Net Income | (4,913) | (8,324) | (27,624) | (35,333) |
| Total Assets | 14,360 | 18,349 | 45,189 | 60,100 |
| Total Debt | 1,983 | 2,206 | 19,801 | 23,262 |
Durect Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Durect Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Durect Comparisons
Industry
Financing
Details
Durect Competitors (36)
One of Durect’s 36 competitors is Hikma Pharmaceuticals, a Corporation company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | Corporation | London, United Kingdom | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Amneal Pharmaceuticals | Formerly PE-Backed | Bridgewater, NJ | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Otsuka Holdings | Corporation | Tokyo, Japan |
Durect Patents
Durect Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4359420-A1 | 25-hydroxy-cholest-5-en-3-sulfate choline and methods for preparing, and uses of, same | Pending | 25-Jun-2021 | ||
| US-20240425545-A1 | 25-hydroxy-cholest-5-en-3-sulfate choline and methods for preparing, and uses of, same | Pending | 25-Jun-2021 | ||
| US-20220273633-A1 | Sustained release drug delivery systems and related methods | Pending | 12-Jan-2021 | ||
| CA-3203561-A1 | Sustained release drug delivery systems and related methods | Pending | 12-Jan-2021 | ||
| EP-4277702-A1 | Sustained release drug delivery systems and related methods | Inactive | 12-Jan-2021 | A61P23/00 |
Durect Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Durect Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Durect Acquisitions (2)
Durect’s most recent deal was a Merger/Acquisition with Southern BioSystems for . The deal was made on 30-Apr-2001.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Southern BioSystems | 30-Apr-2001 | Merger/Acquisition | Drug Delivery | ||
| ALZET Osmotic Pumps | 01-Jan-2000 | Merger/Acquisition | Therapeutic Devices |
Durect ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
41.92 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Pharmaceuticals
Subindustry
of 455
Rank
Percentile
Durect Exits (1)
Durect’s most recent exit was on 01-Jan-2000 from ALZET Osmotic Pumps. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| ALZET Osmotic Pumps | 01-Jan-2000 | Completed |
|
Durect FAQs
-
When was Durect founded?
Durect was founded in 1998.
-
Where is Durect headquartered?
Durect is headquartered in Cupertino, CA.
-
What is the size of Durect?
Durect has 116 total employees.
-
What industry is Durect in?
Durect’s primary industry is Pharmaceuticals.
-
Is Durect a private or public company?
Durect is a Public company.
-
What is Durect’s stock symbol?
The ticker symbol for Durect is DRRX.
-
What is the current stock price of Durect?
As of 16-May-2025 the stock price of Durect is $0.63.
-
What is the current market cap of Durect?
The current market capitalization of Durect is $19.6M.
-
What is Durect’s current revenue?
The trailing twelve month revenue for Durect is $4.42M.
-
Who are Durect’s competitors?
Hikma Pharmaceuticals, Cipla, Amneal Pharmaceuticals, Novartis, and Otsuka Holdings are some of the 36 competitors of Durect.
-
What is Durect’s annual earnings per share (EPS)?
Durect’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
